ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: These BCR‐ABL inhibitors have been reported to improve markedly the prognosis of CML.2, 3, 4, 5, 6 However, maintaining high therapeutic adherence is necessary to obtain the maximum therapeutic effect with BCR‐ABL inhibitors.7 For instance, an adequate blood concentration of imatinib is necessary to obtain the maximum therapeutic effect.8 However, adverse events induced by BCR‐ABL inhibitors decrease therapeutic adherence.